Raub Brock Dividend Growth ETF
HQDG - ETF AI Analysis
Top Page
Raub Brock Dividend Growth ETF (HQDG)
HQDG, the Raub Brock Dividend Growth ETF, earns a solid overall rating thanks to high-quality holdings like Microsoft, TJX, Nasdaq, and Mastercard, which show strong financial performance, positive earnings sentiment, and promising growth in areas such as cloud, AI, and retail expansion. The fund is somewhat held back by holdings like McKesson and AbbVie, where leverage, cash flow, and valuation concerns introduce additional risk. The main risk factor is that several core positions show bearish technical trends and potential overvaluation, which could increase volatility despite their strong business fundamentals.
HQDG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 74.23M
- Region
- North America
- Expense Ratio
- 0.50%
- Beta
- 0.80
- Issuer
- Raub Brock
- Inception Date
- Sep 04, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
HQDG Summary
HQDG, the Raub Brock Dividend Growth ETF, is a U.S.-focused fund that picks large, established companies aiming to grow their dividends over time rather than tracking a fixed index. It leans toward sectors like technology, health care, and industrials, and holds well-known names such as AbbVie and Eli Lilly. Investors might consider HQDG for a mix of potential long-term growth and rising income from dividends, all in one diversified basket of stocks. A key risk is that share prices and dividend payments can still go up and down with the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. That cost is higher than the average index ETF because HQDG is actively managed, with professionals selecting dividend growth stocks rather than simply tracking a market index.
What would affect this ETF?
HQDG could benefit if the U.S. economy stays healthy, supporting earnings and dividend growth for its large holdings in technology, industrials, and health care companies like AbbVie, Eli Lilly, and Mastercard, and if investors continue to favor dividend-focused strategies. On the downside, rising interest rates, slower economic growth, or tighter regulations on drug makers, financial firms, or tech companies could pressure profits and reduce investor demand for growth and dividend stocks in this U.S.-focused ETF.
HQDG Top 10 Holdings
HQDG leans heavily into high-quality U.S. dividend growers, with health care and tech names doing much of the heavy lifting. Eli Lilly, AbbVie, and McKesson have been steadily rising, giving the fund a strong defensive backbone. On the tech side, Microsoft and Texas Instruments add growth flair, with TI in particular acting like a turbocharger for recent returns. Consumer names like Casey’s General Stores and TJX are more mixed, occasionally losing steam and trimming some of the upside. Overall, the fund is U.S.-centric, tilted toward resilient, cash-rich leaders.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MCK | McKesson | 5.45% | $4.03M | $124.99B | 25.97% | 62Neutral |
 CASY | Casey's General | 5.41% | $4.00M | $25.82B | 31.16% | 68Neutral |
 LLY | Eli Lilly & Co | 5.36% | $3.96M | $1.35T | 48.17% | 72Outperform |
 MA | Mastercard | 5.33% | $3.94M | $573.97B | 19.15% | 75Outperform |
 MSI | Motorola Solutions | 5.08% | $3.76M | $87.19B | 33.85% | 70Neutral |
 ECL | Ecolab | 5.05% | $3.73M | $85.83B | 18.36% | 66Neutral |
 NDAQ | Nasdaq | 5.05% | $3.73M | $61.06B | 25.28% | 78Outperform |
 MCO | Moody's | 4.94% | $3.65M | $88.05B | 5.32% | 77Outperform |
 ABBV | AbbVie | 4.93% | $3.65M | $519.48B | 34.37% | 66Neutral |
 MSFT | Microsoft | 4.89% | $3.61M | $3.96T | 5.37% | 79Outperform |
HQDG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HQDG, the sentiment is Positive. The current price of 25.67 is above the 20-day moving average (MA) of 25.23, compared to the 50-day MA of , and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 56.74 is Neutral, neither overbought nor oversold. The STOCH value of 61.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HQDG.
HQDG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| HQDG | $25.67 | $28.00(9.08% Upside) | $74.23M | 0.50% | 73Outperform |
 PAYR | $56.82 | $61.27(7.82% Upside) | $96.72M | 0.40% | 66Neutral |
 FDIV | $28.40 | $32.05(12.83% Upside) | $55.20M | 0.35% | 70Neutral |
 DIVY | $32.01 | $33.91(5.93% Upside) | $29.78M | 0.45% | 69Neutral |
 VUS | $29.07 | $35.10(20.72% Upside) | $17.45M | 0.25% | 70Outperform |
 JHDV | $45.30 | $54.90(21.19% Upside) | $12.72M | 0.34% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HQDG | Raub Brock Dividend Growth ETF | 25.67 | 0.68 | 2.70% | |
| PAYR | Federated Hermes Enhanced Income ETF | 56.82 | 10.13 | 21.70% | |
| FDIV | MarketDesk Focused U.S. Dividend ETF | 28.40 | 2.30 | 8.81% | |
| DIVY | Sound Equity Income ETF | 32.01 | 6.84 | 27.19% | |
| VUS | Virtus US Dividend ETF | 29.07 | 4.59 | 18.75% | |
| JHDV | John Hancock U.S. High Dividend ETF | 45.30 | 6.08 | 15.50% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.